Detalles de la búsqueda
1.
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
Lancet Oncol
; 21(12): 1574-1588, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32971005
2.
Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escalation study 1108.
Cancer
; 126(2): 432-443, 2020 01 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31581306
3.
Durvalumab activity in previously treated patients who stopped durvalumab without disease progression.
J Immunother Cancer
; 8(2)2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32847985
4.
Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort.
Eur J Cancer
; 109: 154-161, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30731276
5.
Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC.
J Thorac Oncol
; 14(10): 1794-1806, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31228626
Resultados
1 -
5
de 5
1
Próxima >
>>